双参柔肝颗粒剂对实验性肝硬化大鼠的治疗作用

Pharmacological Effects of Shuangshen Rougan Keli on Experimental Hepatic Cirrhosis in Rats

双参柔肝颗粒剂 (SS)能有效地阻止复合病因所致的实验性大鼠肝硬变形成。结果表明 ,SS 3 .0 g/kg与 6 .0 g/kg两个剂量组均能使血清GPT、GOT酶活性恢复正常 ;r 谷氨酰转肽酶 (r GT)由 345± 95nmol/s降至 2 0 0± 2 1nmol/s;可以抑制肝纤维增生 ;可使尿中羟脯氨酸 (HYP)排泄增加 ,肝匀浆和血清中HYP均降低 ;使血清脂质过氧化物丙二醛 (MDA)降低 ;可提高超氧化物歧化酶 (SOD)的活力 ;清除甘油三酯 (TG)在体内的积蓄。实验证明 ,该药对肝损伤的修复、阻止肝脂肪变性、防止慢性肝炎向肝硬化发展有效。

Shuangshen Rougan Keli (SS) could effectively blocked the formation of hepatic cirrhosis in rats induced by complex pathogenic causes. Both the two treating groups could restore enzyme activity level. The content of r-GT,SGPT and SGOT in serum decreased from 345±95 nmol/s to 200±21 nmol/s. It could enhance collagen excretion and inhibit fibrin proliferation. Hydroxyproline excretion increased in urine, and decreased in hepatic and decreased in serum. In addition, SS could also clear the storage of triglyceride in the liver. Lower MDA and elevate the activity of SOD. It is suggested that SS has marked effects on enhancing the restoration of damaged hepatic histocytes, on retarding hepatic adipogenesis and necrosis, and on interrupting the derelopment of chronic hepatic cirrhosis.